Navigation Links
Excelera® Specialty Pharmacy Network Joins Merck’s Commitment to Hepatitis C
Date:8/23/2017

The Excelera network consists of point-of-care specialty pharmacies owned by health systems and academic medical centers. The network provides members nationally scaled infrastructure and support to help them develop best practices and gain access to limited-distribution drugs and biologics and restrictive payer agreements so members can provide continuity of care for their patients with complex and chronic conditions requiring specialty drugs and biologics. The network also serves as a national platform for collaboration to optimize outpatient specialty drug therapy for population health.

Specialty pharmaceuticals are expensive drugs that require special handing and administration and are often used to treat the most ill and clinically complex patients. The Excelera organization will partner with Merck to ensure that member health system-based specialty pharmacies have access to these important Hep C medications as well as to macrolide antibacterial drug Dificid®.

“To be able to provide Hep C patients access to these important treatments directly at the point of care ensures the best possible utilization and adherence to these therapies,” said Jim Fox, Chief Executive Officer of the Excelera network.

Chronic HCV

Chronic HCV is a contagious liver disease that can lead to serious liver problems, including cirrhosis (scarring of the liver) or liver cancer. Treatment generally includes antiviral medications intended to clear the virus from the patient's body.

About ZEPATIER ® (elbasvir and grazoprevir) 50mg/100mg Tablets

ZEPATIER is a fixed-dose combination product containing elbasvir, a HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. In the United States, ZEPATIER is indicated for the treatment of chronic HCV GT1 or 4 infection in adults. ZEPATIER is indicated for use with ribavirin (RBV) in certain patient populations. The efficacy of ZEPATIER has not been established in patients who have previously failed treatment with other regimens that included an NS5A inhibitor.

About DIFICID®

DIFICID® is a macrolide antibacterial drug indicated in adults (=18 years of age) for treatment of Clostridium difficile-associated diarrhea (CDAD).

About Excelera

ExceleraRx Corp. supports the Excelera® Specialty Pharmacy Network, a national network of specialty pharmacies based at health systems and academic medical centers, enabling member organizations to gain access to limited distribution drugs and restricted payer agreements. The Excelera network provides national-scale efficiency and collaboration to improve quality and value of outpatient specialty drug therapy for population health outcomes. Excelera’s mission is to “provide tools, technology and best practices around high-performing specialty pharmacy capabilities to network members, so that they can provide integrated, coordinated care to complex patients at the point-of-care leading to improved health outcomes and decreased healthcare costs.” For a current list of Excelera specialty pharmacy network members, or for more information about becoming a member of the Excelera national specialty pharmacy network, visit excelerarx.com or follow us on LinkedIn.

Read the full story at http://www.prweb.com/releases/excelera/specialtypharmacynetwork/prweb14506228.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Heritage Biologics Earns URAC Accreditation in Specialty Pharmacy
2. Natural Trends, Anti-pollution Protection Claims, and New Technologies are the Cornerstones of the Specialty Actives Markets Strong Growth, Finds Kline
3. Ross Optical to Feature Large Diameter & Specialty Optics at Photonics West 2017
4. Proove Biosciences and Specialty Health Announce a Positive Coverage Determination by Leading Nevada Insurer for Genetic Testing
5. Diplomat Publishes New Report on Specialty Drugs Approved in 2015 and Expected for 2016
6. Specialty Pharmacy Times Joins BPA Worldwide
7. The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience
8. Armada to Launch Specialty Pharmacy Workflow Platform
9. BioPlus Specialty Pharmacy Names Liz Salter as New Vice President of Managed Care
10. Developing Nations Emerge as the Building Blocks of the Asia-Pacific Amino Acids and Specialty Proteins Market, says Frost & Sullivan
11. BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... NY (PRWEB) , ... October 12, 2017 , ... ... of Sciences today announced the three Winners and six Finalists of the 2017 ... given annually by the Blavatnik Family Foundation and administered by the New York ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... ... , ... Personal eye wash is a basic first aid supply for any work environment, but ... do you rinse first if a dangerous substance enters both eyes? It’s one less decision, ... its unique dual eye piece. , “Whether its dirt and debris, or an acid or ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):